Rubilon 50mg Injection

About

Rubilon 50mg Injection contains Epirubicin, an anthracycline topoisomerase II inhibitor used in the treatment of various cancers. It exerts its cytotoxic effects through multiple mechanisms, including intercalation into DNA, inhibition of topoisomerase II, and generation of free radicals. These actions lead to DNA damage, inhibition of nucleic acid synthesis, and ultimately, apoptosis in rapidly proliferating cancer cells. Epirubicin is administered intravenously and is a key component in many chemotherapy regimens, particularly for solid tumors.

Its broad spectrum of activity makes it valuable in both adjuvant and metastatic settings, aiming to reduce tumor burden and improve patient survival. Due to its mechanism, careful monitoring for potential side effects, especially cardiotoxicity, is essential during treatment.

Uses

• Adjuvant breast cancer
• Metastatic breast cancer
• Ovarian cancer
• Gastric cancer

Directions For Use

Administered intravenously by a healthcare professional. Dosage and frequency are determined by the physician based on the specific cancer and patient factors.

Benefits

• Effective against a broad spectrum of solid tumors.
• A cornerstone in many chemotherapy regimens.
• Can improve disease-free and overall survival.
• Well-established efficacy profile.
• Part of standard treatment protocols.
• Can be used in combination with other agents.

Side Effects

• Myelosuppression (neutropenia, thrombocytopenia, anemia)
• Nausea
• Vomiting
• Alopecia (hair loss)
• Stomatitis/Mucositis
• Cardiotoxicity (dose-dependent)
• Fatigue
• Diarrhea
• Anorexia
• Local injection site reactions
• Red urine (transient, harmless)
• Amenorrhea

Safety Measures

• Alcohol - Avoid or limit alcohol due to potential for increased gastrointestinal irritation and liver strain during chemotherapy.
• Pregnancy - Contraindicated. Epirubicin can cause fetal harm. Use effective contraception during treatment and for 6 months after the last dose.
• Breastfeeding - Contraindicated. It is unknown if epirubicin is excreted in human milk; advise women not to breastfeed during treatment.
• Liver - Use with extreme caution in patients with hepatic impairment. Dose reductions are necessary; monitor liver function closely.
• Kidney - Use with caution in patients with severe renal impairment. Dose adjustments may be considered, though renal excretion is minor.
• Lung - Monitor for any new or worsening respiratory symptoms, though direct lung toxicity is less common.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.